Literature DB >> 34778769

Synthesis and biological evaluation of selective phosphonate-bearing 1,2,3-triazole-linked sialyltransferase inhibitors.

Christopher Dobie1, Andrew P Montgomery1, Rémi Szabo1, Haibo Yu1,2, Danielle Skropeta1,2.   

Abstract

The critical role of sialyltransferase (ST) enzymes in tumour cell growth and metastasis, as well as links to multi-drug and radiation resistance, has seen STs emerge as a target for potential antimetastatic cancer treatments. One promising class of ST inhibitors that improve upon the pharmacokinetic issues of previous inhibitors is the 1,2,3-triazole-linked transition-state analogues. Herein, we present the design and synthesis of a new generation of 1,2,3-triazole-linked sialyltransferase inhibitors, along with their biological evaluation demonstrating increased potency for phosphonate bearing compounds. The six most promising inhibitors presented in this work exhibited a greater number of binding modes for hST6Gal I over hST3Gal I, with K i ranging from 3-55 μM. This work highlights phosphonate bearing triazole-linked compounds as a promising class of synthetically accessible ST inhibitors that warrant further investigation. This journal is © The Royal Society of Chemistry.

Entities:  

Year:  2021        PMID: 34778769      PMCID: PMC8528205          DOI: 10.1039/d1md00079a

Source DB:  PubMed          Journal:  RSC Med Chem        ISSN: 2632-8682


  48 in total

Review 1.  Current trends in the structure-activity relationships of sialyltransferases.

Authors:  Magali Audry; Charlotte Jeanneau; Anne Imberty; Anne Harduin-Lepers; Philippe Delannoy; Christelle Breton
Journal:  Glycobiology       Date:  2010-11-22       Impact factor: 4.313

2.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

3.  Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis.

Authors:  Chih-Wei Fu; Han-En Tsai; Wei-Sheng Chen; Tzu-Ting Chang; Chia-Ling Chen; Pei-Wen Hsiao; Wen-Shan Li
Journal:  J Med Chem       Date:  2020-12-28       Impact factor: 7.446

Review 4.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

Review 5.  Advancement of Sialyltransferase Inhibitors: Therapeutic Challenges and Opportunities.

Authors:  Rémi Szabo; Danielle Skropeta
Journal:  Med Res Rev       Date:  2016-09-28       Impact factor: 12.944

6.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.

Authors:  Garrett M Morris; Ruth Huey; William Lindstrom; Michel F Sanner; Richard K Belew; David S Goodsell; Arthur J Olson
Journal:  J Comput Chem       Date:  2009-12       Impact factor: 3.376

7.  Asymmetric epoxidation of fluoroolefins by chiral dioxirane. Fluorine effect on enantioselectivity.

Authors:  O Andrea Wong; Yian Shi
Journal:  J Org Chem       Date:  2009-11-06       Impact factor: 4.354

Review 8.  Hypersialylation in Cancer: Modulation of Inflammation and Therapeutic Opportunities.

Authors:  Emily Rodrigues; Matthew S Macauley
Journal:  Cancers (Basel)       Date:  2018-06-18       Impact factor: 6.639

9.  Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model.

Authors:  Alessandro Natoni; Mariah L Farrell; Sophie Harris; Carolyne Falank; Lucy Kirkham-McCarthy; Matthew S Macauley; Michaela R Reagan; Michael O'Dwyer
Journal:  Haematologica       Date:  2020-01-31       Impact factor: 9.941

Review 10.  Hallmarks of glycosylation in cancer.

Authors:  Jennifer Munkley; David J Elliott
Journal:  Oncotarget       Date:  2016-06-07
View more
  1 in total

1.  Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer.

Authors:  Bo Qin; Qian Bai; Dan Yan; Fanxiang Yin; Zhu Zhu; Chaoyuan Xia; Yang Yang; Yi Zhao
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.756

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.